BACKGROUND: The contribution of induction chemotherapy (IC) before preoperative chemoradiation for esophageal cancer (EC) is not known. We hypothesized that IC would increase the rate of pathologic complete response (pathCR). METHODS:Trimodality-eligibile patients were randomized to receive no IC (Arm A) or IC (oxaliplatin/FU; Arm B) before oxaliplatin/FU/radiation. Surgery was attempted ∼5-6 weeks after chemoradiation. The pathCR rate, post-surgery 30-day mortality, overall survival (OS), and toxic effects were assessed. Bayesian methods and Fisher's exact test were used. RESULTS:One hundred twenty-six patients were randomized dynamically to balance the two arms for histology, baseline stage, gender, race, and age. Fifty-five patients in Arm A and 54 in Arm B underwent surgery. The median actuarial OS for all patients (54 deaths) was 45.62 months [95% confidence interval (CI), 27.63-NA], with median OS 45.62 months (95% CI 25.56-NA) in Arm A and 43.68 months (95% CI 27.63-NA) in Arm B (P = 0.69). The pathCR rate in Arm A was 13% (7 of 55) and 26% (14 of 54) in Arm B (two-sided Fisher's exact test, P = 0.094). Safety was similar in both arms. CONCLUSIONS: These data suggest that IC produces non-significant increase in the pathCR rate and does not prolong OS. Further development of IC before chemoradiation may not be beneficial. Clinical trial no.: NCT 00525915 (www.clinicaltrials.gov).
RCT Entities:
BACKGROUND: The contribution of induction chemotherapy (IC) before preoperative chemoradiation for esophageal cancer (EC) is not known. We hypothesized that IC would increase the rate of pathologic complete response (pathCR). METHODS: Trimodality-eligibile patients were randomized to receive no IC (Arm A) or IC (oxaliplatin/FU; Arm B) before oxaliplatin/FU/radiation. Surgery was attempted ∼5-6 weeks after chemoradiation. The pathCR rate, post-surgery 30-day mortality, overall survival (OS), and toxic effects were assessed. Bayesian methods and Fisher's exact test were used. RESULTS: One hundred twenty-six patients were randomized dynamically to balance the two arms for histology, baseline stage, gender, race, and age. Fifty-five patients in Arm A and 54 in Arm B underwent surgery. The median actuarial OS for all patients (54 deaths) was 45.62 months [95% confidence interval (CI), 27.63-NA], with median OS 45.62 months (95% CI 25.56-NA) in Arm A and 43.68 months (95% CI 27.63-NA) in Arm B (P = 0.69). The pathCR rate in Arm A was 13% (7 of 55) and 26% (14 of 54) in Arm B (two-sided Fisher's exact test, P = 0.094). Safety was similar in both arms. CONCLUSIONS: These data suggest that IC produces non-significant increase in the pathCR rate and does not prolong OS. Further development of IC before chemoradiation may not be beneficial. Clinical trial no.: NCT 00525915 (www.clinicaltrials.gov).
Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: Lucian R Chirieac; Stephen G Swisher; Jaffer A Ajani; Ritsuko R Komaki; Arlene M Correa; Jeffrey S Morris; Jack A Roth; Asif Rashid; Stanley R Hamilton; Tsung-Teh Wu Journal: Cancer Date: 2005-04-01 Impact factor: 6.860
Authors: Jaffer A Ajani; James S Barthel; David J Bentrem; Thomas A D'Amico; Prajnan Das; Crystal S Denlinger; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; A Craig Lockhart; Mary F Mulcahy; Mark B Orringer; Raymond U Osarogiagbon; James A Posey; Aaron R Sasson; Walter J Scott; Stephen Shibata; Vivian E M Strong; Thomas K Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D Wright Journal: J Natl Compr Canc Netw Date: 2011-08-01 Impact factor: 11.908
Authors: Tsung-Teh Wu; Lucian R Chirieac; Susan C Abraham; Alyssa M Krasinskas; Huamin Wang; Asif Rashid; Arlene M Correa; Wayne L Hofstetter; Jaffer A Ajani; Stephen G Swisher Journal: Am J Surg Pathol Date: 2007-01 Impact factor: 6.394
Authors: J A Ajani; R Komaki; J B Putnam; G Walsh; J Nesbitt; P W Pisters; P M Lynch; A Vaporciyan; R Smythe; S Lahoti; I Raijman; S Swisher; F D Martin; J A Roth Journal: Cancer Date: 2001-07-15 Impact factor: 6.860
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: Pooja Rohatgi; Stephen G Swisher; Arlene M Correa; Tsung-T Wu; Zhongxing Liao; Ritsuko Komaki; Garrett L Walsh; Ara A Vaporciyan; David C Rice; Jack A Roth; Jaffer A Ajani Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: Adam C Berger; Jeffrey Farma; Walter J Scott; Gary Freedman; Louis Weiner; Jonathan D Cheng; Hao Wang; Melvyn Goldberg Journal: J Clin Oncol Date: 2005-03-21 Impact factor: 44.544
Authors: Nabil P Rizk; Ennapadam Venkatraman; Manjit S Bains; Bernard Park; Raja Flores; Laura Tang; David H Ilson; Bruce D Minsky; Valerie W Rusch Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Geoffrey Y Ku; Manjit S Bains; Do Joong Park; Yelena Y Janjigian; Valerie W Rusch; Nabil P Rizk; Sam S Yoon; Brittanie Millang; Marinela Capanu; Karyn A Goodman; David H Ilson Journal: J Gastrointest Oncol Date: 2016-12
Authors: Maria Alsina; Fernando Rivera; Francisco Javier Ramos; Maica Galán; Rafael López; Pilar García-Alfonso; José Enrique Alés-Martinez; Bernardo Queralt; Antonio Antón; Alfredo Carrato; Cristina Grávalos; Maria José Méndez-Vidal; Carlos López; Inmaculada Ruiz de Mena; Josep Tabernero; Jordi Giralt; Enrique Aranda Journal: Target Oncol Date: 2018-02 Impact factor: 4.493
Authors: Geoffrey Y Ku; Anuja Kriplani; Yelena Y Janjigian; David P Kelsen; Valerie W Rusch; Manjit Bains; Joanne Chou; Marinela Capanu; Abraham J Wu; Karyn A Goodman; David H Ilson Journal: Cancer Date: 2016-05-06 Impact factor: 6.860
Authors: Mian Xi; Zhongxing Liao; Wayne L Hofstetter; Ritsuko Komaki; Linus Ho; Steven H Lin Journal: J Nucl Med Date: 2017-05-18 Impact factor: 10.057
Authors: Kazuto Harada; Xuemei Wang; Yusuke Shimodaira; Tara Sagebiel; Manoop S Bhutani; Jeffrey H Lee; Brian Weston; Elena Elimova; Quan Lin; Fatemeh G Amlashi; Dilsa Mizrak Kaya; Anthony Lopez; Mariela A Blum Murphy; Jack A Roth; Stephen G Swisher; Heath D Skinner; Wayne L Hofstetter; Jane E Rogers; Irene Thomas; Dipen M Maru; Ritsuko Komaki; Garrett Walsh; Jaffer A Ajani Journal: Target Oncol Date: 2018-02 Impact factor: 4.493
Authors: Kazuki Sudo; Lianchun Xiao; Roopma Wadhwa; Hironori Shiozaki; Elena Elimova; Takashi Taketa; Mariela A Blum; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William A Ross; Ritsuko Komaki; David C Rice; Stephen G Swisher; Wayne L Hofstetter; Dipen M Maru; Heath D Skinner; Jaffer A Ajani Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544